- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04082299
Immune Response followingTdap Vaccine in Pregnancy
December 5, 2022 updated by: Hillel Yaffe Medical Center
Immune Response Following Tdap Vaccination in Pregnant vs. Non Pregnant Women
Pregnancy involves changes in immune response.
The investigators aim to evaluate the immune response to Tdap in pregnancy in comparison to non pregnant women usig proteomics and gene sequencing.
Study Overview
Status
Recruiting
Detailed Description
Many vaccine-preventable diseases, like influenza, pertussis, and tetanus cause substantial morbidity and mortality in pregnant women, newborns and infants.
Immunization during pregnancy has the potential to provide protection to the newborn and infant by the transplacental transfer of vaccine-specific maternal antibodies.
However, the immunobiology underlying immunization during pregnancy, that leads to the protection of the newborn are not understood.
Current vaccine formulations were designed for and tested in non-pregnant populations; yet substantial immune modulations take place during different stages of pregnancy and potentially can impact the humoral response following maternal immunization.
The investigators thus have insufficient data on quantity and quality of the immune response during pregnancy and how this relates to immunity provided from the mother to the newborn.
First, The investigators hypothesize that the nature and breadth of the humoral immune response following vaccination differs in pregnant and non-pregnant vaccinees.
Next, The investigators hypothesize that the vaccine-specific antibodies that cross the placenta, comprise distinct repertoire features thus, the placenta functions as a differential barrier for antibody transfer.
To test these hypotheses, The investigators will use proteomic and genomic/transcriptomic measurements of antibody repertoires in the maternal and cord blood compartments.
The measurements will be based on antibody clonal diversity/frequency, V(D)J germline usage and SHM, where we expect to find changes in i) vaccine-specific B cell frequency, antibody clonal diversity, germline usage and SHM in pregnant women and ii) distinct repertoire features in the transplacental vaccine-specific antibody compartment compared the maternal compartment.
The investigators will utilize deep sequencing and proteomic technologies to provide, for the first time, insight into the immunobiology of a promising intervention aimed to prevent early life infectious morbidity and mortality and establish new research avenues for vaccine research in vulnerable populations.
Study Type
Observational
Enrollment (Anticipated)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rinat Gabbay-Benziv, Dr
- Phone Number: +972-4-7744602
- Email: rinatg@hymc.gov.il
Study Contact Backup
- Name: Yariv Wine, PhD
- Phone Number: +972-3-6408723
- Email: yariv.wine@gmail.com
Study Locations
-
-
-
Hadera, Israel, 3810101
- Recruiting
- Hillel Yaffe Medical Center
-
Contact:
- Osnat Palgi, Bsc
- Phone Number: +972-4-7744602
- Email: osnatp@hymc.gov.il
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
pregnant and non pregnant women
Description
Inclusion Criteria for pregnant women (cohort 1):
- age between 18-45 years
- pregnant women who expected to have Tdap vaccine
- Informed Consent Form signature
Inclusion Criteria for non pregnant women (cohort 2):
- age between 18-45 years
- non pregnant women who expected to have Tdap vaccine
- Informed Consent Form signature
Exclusion Criteria (cohort 1 and 2):
- any background immune diseases- autoimmune conditions or cancer.
- women who take immunosuppressive/ immunomodulatory medications
- a patient has received Tdap vaccine in 6 months prior to study entry.
- no will to signed the Informed Consent Form.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Pregnant women
pregnant women expected to be vaccinate with Tdap vaccine during their 3th trimester
|
Non pregnant women
Non pregnant women expected to be vaccinate with Tdap vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune response following Tdap vaccine
Time Frame: 4 months
|
Characterization of immune response following Tdap vaccine.
|
4 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Rinat Gabbay-Benziv, Dr, Hillel Yaffe Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 12, 2019
Primary Completion (Anticipated)
September 1, 2023
Study Completion (Anticipated)
September 1, 2023
Study Registration Dates
First Submitted
September 5, 2019
First Submitted That Met QC Criteria
September 6, 2019
First Posted (Actual)
September 9, 2019
Study Record Updates
Last Update Posted (Estimate)
December 6, 2022
Last Update Submitted That Met QC Criteria
December 5, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0079-19-HYMC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diphtheria-Tetanus-acellular Pertussis Vaccines
-
GlaxoSmithKlineCompletedTetanus | Diphtheria | Acellular Pertussis | Diphtheria-Tetanus-acellular Pertussis VaccinesAustralia
-
GlaxoSmithKlineCompletedTetanus | Diphtheria | Acellular Pertussis | Diphtheria-Tetanus-acellular Pertussis VaccinesUnited States
-
GlaxoSmithKlineCompletedDiphtheria-Tetanus-acellular Pertussis VaccinesFinland, Australia, Spain, Italy, Canada, Czechia
-
GlaxoSmithKlineCompletedDiphtheria-Tetanus-acellular Pertussis VaccinesKorea, Republic of
-
GlaxoSmithKlineCompletedDiphtheria-Tetanus-acellular Pertussis VaccinesRussian Federation
-
GlaxoSmithKlineCompletedTetanus | Diphtheria | Acellular Pertussis | Diphtheria-Tetanus-acellular Pertussis Vaccines | Aspergillosis, Allergic BronchopulmonaryColombia
-
GlaxoSmithKlineCompletedTetanus | Diphtheria | Acellular Pertussis | Diphtheria-Tetanus-acellular Pertussis Vaccines | PoliomyelitisKorea, Republic of
-
GlaxoSmithKlineTerminatedDiphtheria-Tetanus-Acellular PertussisColombia
-
ABO Holdings, Inc.Active, not recruitingTetanus, Diphtheria and Acellular Pertussis VaccinationUnited States
-
CanSino Biologics Inc.Active, not recruitingDiphtheria, Tetanus and Acellular PertussisChina